Financière de Tubize SA (TUB.BR)
EUR 132.8
(5.23%)
EUR 132.8
(5.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 78.62 Million EUR | 68.25% |
| 2022 | 46.73 Million EUR | 1028.5% |
| 2021 | 4.14 Million EUR | -87.27% |
| 2020 | 32.53 Million EUR | -62.19% |
| 2019 | 86.03 Million EUR | -39.02% |
| 2018 | 141.08 Million EUR | -26.01% |
| 2017 | 190.69 Million EUR | -20.66% |
| 2016 | 240.33 Million EUR | -15.59% |
| 2015 | 284.72 Million EUR | 54.74% |
| 2014 | 184 Million EUR | -17.01% |
| 2013 | 221.71 Million EUR | -13.12% |
| 2012 | 255.2 Million EUR | -10.71% |
| 2011 | 285.81 Million EUR | -8.99% |
| 2010 | 314.03 Million EUR | -7.55% |
| 2009 | 339.69 Million EUR | -3.15% |
| 2008 | 350.74 Million EUR | 4054.67% |
| 2007 | -8.86 Million EUR | -104.15% |
| 2006 | 213.78 Million EUR | 122.25% |
| 2005 | 96.19 Million EUR | -10.76% |
| 2004 | 107.78 Million EUR | -12.73% |
| 2003 | 123.51 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 30.49 Million EUR | 0.0% |
| 2023 FY | 78.62 Million EUR | 68.25% |
| 2023 Q2 | 46.31 Million EUR | 0.0% |
| 2023 Q4 | 78.62 Million EUR | 0.0% |
| 2022 Q2 | 44.72 Million EUR | 0.0% |
| 2022 FY | 46.73 Million EUR | 1028.5% |
| 2022 Q4 | 46.73 Million EUR | 0.0% |
| 2021 FY | 4.14 Million EUR | -87.27% |
| 2021 Q4 | 4.14 Million EUR | 0.0% |
| 2021 Q2 | -2.26 Million EUR | 0.0% |
| 2020 FY | 32.53 Million EUR | -62.19% |
| 2020 Q4 | 32.53 Million EUR | 0.0% |
| 2020 Q2 | 30.29 Million EUR | 0.0% |
| 2019 Q2 | 84.97 Million EUR | 0.0% |
| 2019 Q4 | 86.03 Million EUR | 0.0% |
| 2019 FY | 86.03 Million EUR | -39.02% |
| 2018 Q4 | 141.08 Million EUR | 0.0% |
| 2018 FY | 141.08 Million EUR | -26.01% |
| 2018 Q2 | 137.82 Million EUR | 0.0% |
| 2017 Q2 | 189.11 Million EUR | 0.0% |
| 2017 FY | 190.69 Million EUR | -20.66% |
| 2017 Q4 | 190.69 Million EUR | 0.0% |
| 2016 FY | 240.33 Million EUR | -15.59% |
| 2016 Q2 | 237.57 Million EUR | 0.0% |
| 2016 Q4 | 240.33 Million EUR | 0.0% |
| 2015 FY | 284.72 Million EUR | 54.74% |
| 2015 Q2 | 143.78 Million EUR | 0.0% |
| 2015 Q4 | 284.72 Million EUR | 0.0% |
| 2014 Q4 | 184 Million EUR | 0.0% |
| 2014 Q2 | 178.86 Million EUR | 0.0% |
| 2014 FY | 184 Million EUR | -17.01% |
| 2013 FY | 221.71 Million EUR | -13.12% |
| 2013 Q4 | 221.71 Million EUR | 0.0% |
| 2013 Q2 | 209.36 Million EUR | 0.0% |
| 2012 Q4 | 255.2 Million EUR | 0.0% |
| 2012 Q2 | 296.84 Million EUR | 0.0% |
| 2012 FY | 255.2 Million EUR | -10.71% |
| 2011 Q2 | 273.69 Million EUR | 0.0% |
| 2011 FY | 285.81 Million EUR | -8.99% |
| 2011 Q4 | 285.81 Million EUR | 0.0% |
| 2010 Q2 | 301.88 Million EUR | 0.0% |
| 2010 FY | 314.03 Million EUR | -7.55% |
| 2010 Q4 | 314.03 Million EUR | 0.0% |
| 2009 Q4 | 339.69 Million EUR | 0.0% |
| 2009 FY | 339.69 Million EUR | -3.15% |
| 2008 FY | 350.74 Million EUR | 4054.67% |
| 2007 FY | -8.86 Million EUR | -104.15% |
| 2006 FY | 213.78 Million EUR | 122.25% |
| 2005 FY | 96.19 Million EUR | -10.76% |
| 2004 FY | 107.78 Million EUR | -12.73% |
| 2003 FY | 123.51 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nicox S.A. | 13.89 Million EUR | -465.893% |
| European Medical Solutions | 13.93 Million EUR | -464.39% |
| FERMENTALG | 4.19 Million EUR | -1775.153% |
| argenx SE | -1.83 Billion EUR | 104.281% |
| BioSenic S.A. | 28.04 Million EUR | -180.364% |
| Celyad Oncology SA | -6.1 Million EUR | 1388.515% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 413.098% |
| Onward Medical N.V. | -12.89 Million EUR | 709.781% |
| Oxurion NV | 10.71 Million EUR | -634.128% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | 28690.967% |
| UCB SA | 2.17 Billion EUR | 96.388% |